Effect of Xolair on Airway Hyperresponsiveness

Conditions

• Allergic Asthma

Eligibility Criteria

Sex

ALL

Age

19 Years - 50 Years

Healthy Volunteers

Not accepted

Interventions

• Omalizumab — DRUG
  0.016 mg/kg IgE
• Placebo for Omalizumab — DRUG
  Placebo
• omalizumab — DRUG
  Monoclonal antibody against IgE. 0.016 mg/kg IgE

Study Details

The purpose of this study is to determine if Xolair can reduce the abnormal increase in limitation to airflow in patients with asthma in a relatively short time period. Another purpose is to determine if Xolair will decrease the amount of inflammation in the lungs of an asthmatic patient in the same time period.

Key Dates

Start date

Jan 31, 2004

Status verified

Sep 2011

Primary completion

Sep 30, 2011

Completion

Sep 30, 2011

Study Design

Enrollment

22 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Placebo Comparator: Control
  Placebo
• Experimental: 2
  Omalizumab

Primary Outcome Measure

To determine if treatment with omalizumab induces changes in PC20 values to methacholine bronchoprovocation challenges and/or PC15 values to hypertonic saline-induced bronchoprovocation challenges in a time-dependent manner in steroid naive subjects [ Time Frame: post treatment ]

Locations (1)

Find similar trials in Omaha, NE

Related Studies

• Asthma Inflammation Research
  EARLY_PHASE1 · Enrolling By Invitation · The Cleveland Clinic · Cleveland, Ohio
• A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
  PHASE3 · Recruiting · Bridgette Jones · Kansas City, Missouri